Objective: The possible different prevalence of arterial hypertension (AH), type 2 diabetes mellitus (T2DM), dyslipidaemia (DL) and vertebral fractures (FX) between patients with bilateral and unilateral adrenal incidentalomas (BAI and UAI, respectively) with and without subclinical hypercortisolism (SH) is unknown. In this study we compared the prevalence of AH, T2DM, DL and FX in BAI and UAI patients in relation to SH. Design: Prospective study. Methods: In 175 UAI and 38 BAI patients, we evaluated BMI, spinal and femoral bone mineral density (LS and FN BMD, respectively) and the presence of AH, T2DM, DL and FX. SH was diagnosed in the presence of R2 of the following: urinary free cortisol levels O193 nmol/24 h, serum cortisol levels after 1 mg dexamethasone suppression test O83 nmol/l or ACTH levels !2.2 pmol/l. Results: Age, BMI and cortisol secretion were comparable, while FN BMD was lower in BAI than in UAI patients (K0.45G0.86 vs 0.09G1.07, PZ0.004). The prevalence of SH, AH, T2DM, and DL was comparable, while the prevalence of FX was higher in BAI than in UAI (52.6 vs 28%, PZ0.007). The presence of FX was associated with BAI (odds ratio (OR) 2.6, 95% confidence interval (95% CI) 1.2-5.6, PZ0.016), after adjusting for SH (OR 1.77, 95% CI 0.85-3.7, PZ0.12), BMI (OR 1.06, 95% CI 0.98-1.13, PZ0.1), age (OR 1.07, 95% CI 1.04-1.11, PZ0.0001) and LS BMD (OR 1.31, 95% CI 1.03-1.67, PZ0.03). Conclusion: BAI patients have an increased FX risk than UAI ones. Further studies should investigate the causes of bone involvement in BAI patients.
Introduction
The term adrenal incidentalomas (AI) is generally used to define the masses larger than 1 cm, affecting the adrenal gland (1) , detected incidentally during imaging procedures performed for unrelated diseases. These masses are more frequently unilateral incidentalomas (UAI), but in about 15% of cases they present as bilateral (2, 3) . Bilateral adrenal incidentalomas (BAI) may be: metastatic diseases of the adrenal glands, the contemporary presence of two unilateral adenomas or the expression of ACTH-independent macronodular adrenal hyperplasia. The pathogenesis of the adrenal tumours is largely unknown. Acquired somatic genetic changes (i.e. B-catenin gene mutations) have been described in sporadic adrenal tumours, while the activation of the cAMP signalling pathway has been found in macronodular adrenal hyperplasia (4, 5, 6) . In addition, the N363S variant of the glucocorticoid receptor gene, associated with an increased sensitivity to glucocorticoids, seems to be more frequent in BAI than in UAI patients, suggesting a possible role of this polymorphism in the formation of bilateral adrenal masses (7) . As a consequence, if the pathogenesis of UAI and BAI was different, the clinical consequences could be different.
Subclinical hypercortisolism (SH) is a condition of biochemical cortisol excess in the absence of the typical features of overt hypercortisolism. It is reported in the 5-30% of patients with AI, accordingly to the various diagnostic criteria used in the literature (8, 9, 10) . In patients with BAI, the prevalence of SH has been reported to be even higher, in relation to the tumour size (11) .
SH has been associated with an increased prevalence of arterial hypertension (AH) and metabolic alterations such as dyslipidaemia (DL) and type 2 diabetes mellitus (T2DM) (12) , and with an increased risk of osteoporosis and vertebral fractures (FX) (13) .
Few studies have evaluated the clinical consequences of SH in BAI. The prevalence of T2DM was found to be higher in patients with BAI as compared with UAI, whereas hypertension, hyperlipidaemia, coronary artery disease and adrenal function were similar (7) . Data about bone complications in these patients are lacking.
In this study, we aimed to compare data of cortisol secretion, metabolic and bone complications in UAI and BAI patients.
Subjects and methods

Subjects
The study was performed in two referral Italian Endocrinology Units: 'Fondazione IRCCS Cà Granda-Ospedale Maggiore Policlinico', Milan and 'Casa Sollievo della Sofferenza', IRCCS, San Giovanni Rotondo, Foggia. Between January 2008 and September 2011 we enrolled 213 consecutive patients: 175 with UAI (116 F; 59 M) and 38 patients with BAI (24 F; 14 M). Written informed consent was obtained from all subjects, and the study was approved by our Ethics Committees.
All AI were discovered by abdominal ultrasound or computed tomography (CT), performed for the evaluation of unrelated diseases (such as renal or biliary colic, non-specific abdominal pain, or during a normal checkup). The findings of AI by ultrasound were confirmed with CT. At CT all adrenal masses were O1 cm in diameter, homogeneous and hypodense and with wellshaped features, consistent with the diagnosis of adrenocortical adenomas. Among patients with BAI eight had bilateral discrete adenomas and 30 had bilateral macronodular hyperplasia.
Exclusion criteria were hypogonadism (in males), depression and alcoholism, diseases and administration of drugs influencing cortisol and dexamethasone metabolism or cortisol secretion, signs or symptoms of cortisol excess (i.e. moon facies, striae rubrae, skin atrophy or buffalo hump), history of malignant disease, congenital adrenal hyperplasia, infection (e.g. tuberculosis, fungal), haemorrhage, pheochromocytoma, amyloidosis or infiltrative disease potentially affecting the adrenal glands. Moreover, all patients taking PPARG agonists and/or any anti-osteoporotic drugs (other than calcium and/or vitamin D) for more than 1 year before entering the study were excluded.
In all patients, the diagnosis of pheochromocytoma was ruled out by measuring 24-h urinary metanephrines. Moreover, in hypertensive patients the presence of primary hyperaldosteronism was excluded by appropriate hormonal measurements (plasma aldosterone levels and renin activity in upright position).
In all patients, the presence of the possible consequences of cortisol excess such as AH, T2DM, DL, osteoporosis and FX was assessed. Subjects with systolic blood pressure of R140 mmHg and/or diastolic blood pressure R90 mmHg and/or on antihypertensive treatment were defined as hypertensive (14) . Diabetes mellitus was diagnosed using WHO criteria (15) . DL was defined as serum triglyceride levels of R1.7 mmol/l, or HDL cholesterol levels of !1.0 mmol/l in men and !1.3 mmol/l in women. Patients were also considered dyslipidemic if any anti-dyslipidemic treatment was given (16) .
In all patients, we measured 24-h urinary free cortisol (UFC, normal values: 27.6-193 nmol/24 h), plasma ACTH at 0800 h (normal values: 2.2-4.4 pmol/l) and serum cortisol levels at 0800 h after 1 mg overnight dexamethasone suppression test (1 mg DST).
We diagnosed SH in the presence of at least two out of the three parameters: UFC O193 nmol/24 h, 1 mg DST O83 nmol/l or ACTH levels !2.2 pmol/l. We decided to use these criteria as they have been previously substantiated on a clinical basis (17) . In SH patients without clearly suppressed ACTH levels (i.e. !5 pg/ml, !1.1 pmol/l), a CRH stimulation test has been performed to rule out Cushing's disease.
Methods
Serum and urinary samples were collected and stored at K20 8C until assayed. In each patient, serum ACTH levels (mean of three determinations at 20-min intervals) were measured by IRMA (BRAHMS Diagnostica GmbH, Berlin, Germany), serum cortisol and UFC levels (after dichloromethane extraction) were determined immunofluorimetrically by TDX-FLX Abbott, GmbH, Diagnostika kits. The intra-and interassay coefficients of variation (CV) were !15% for ACTH and !10% for all other assays.
In all patients, serum calcium, albumin, 24-h urinary calcium and ALP (reference interval 35-120 U/l) were measured by standard colorimetric techniques. Total calcium was corrected for serum albumin. Serum intact parathyroid hormone was measured by chemiluminescent method (Nichols Institute Diagnostic, San Juan Capistrano, CA, USA) with intra-and interassay CV of 5.1 and 8.2% respectively (reference interval 10-60 pg/ml), and 25-hydroxy-vitamin D by RIA (DiaSorin, Milan, Italy). Serum total testosterone levels were assessed by immunofluorometric assay (Perkin-Elmer AutoDELFIA, Wallac Oy, Turku, Finland).
Bone mineral density (BMD) was measured by dualenergy X-ray absorptiometry (DXA) (Hologic Discovery, Watham, MA, USA) at lumbar spine (LS, in vivo precision 1.0%) and femoral neck (FN, in vivo precision 1.8%). Individual BMD values were expressed as SD units (Z-values) in relation to our reference population (18) . Fractured vertebrae were excluded from BMD measurement. No patient had a diagnosis of osteoporosis before entering the study.
Conventional spinal radiographs in lateral (T4-L4) and antero-posterior (AP) projection (L1-L4) were obtained in all subjects with standardised technique. Two trained radiologists, who were blinded to BMD and hormonal data, independently reviewed the radiographs. The radiologists discussed questionable cases to agree on the diagnosis; the inter-rate reliability between the two radiologists was good (kZ0.82). FX were diagnosed on visual inspection using the semiquantitative visual assessment previously described by Genant et al. (19) . According to this technique, fractures assessed on lateral thoracolumbar spine radiographs were defined as reductions of more than 20% in anterior, middle or posterior vertebral height.
Statistical analysis
Statistical analysis was performed by SPSS version 18.0 statistical package (SPSS, Inc.). The results are expressed as meanGS.D. Categorical variables were compared by c 2 test. Comparison of continuous variables among the different groups was performed using one-way ANOVA and Bonferroni post-hoc test, as appropriate.
Logistic regression analysis assessed the association between the presence of FX or AH and the following independent variables: age, gender, BMI, LS BMD (only for FX), presence of SH, presence of UAI or BAI, years since menopause and the presence of menopause. General linear modelling was used for comparing LS and FN BMD between BAI patients with SH and BAI patients without SH after adjusting for BMI. P values of !0.05 were considered significant.
Results
The clinical and biochemical features of BAI and UAI patients are reported in Table 1 . The parameters such as age, BMI, gender, years since menopause (in females), testosterone levels (in males), bone metabolism and cortisol secretion were comparable between the two groups. The sum of the largest diameters of the adrenal tumours in BAI patients was greater than the diameter of the adenoma in UAI patients. FN and LS BMD tended to be lower in patients with BAI when compared with that of UAI, even without reaching the statistical significance for LS BMD (PZ0.08), possibly due to the wide SD. The prevalence of premenopausal females, SH, AH, T2DM and DL was comparable between groups, while the prevalence of FX was higher in BAI than in UAI. Finally, the prevalence of patients taking medications that may influence BMD (e.g. statins, b-adrenergic blockers, loop-diuretics, thiazide diuretics) was comparable between the BAI and UAI groups (data not shown).
The comparisons between BAI patients with and without SH (BAI SHC vs BAI SHK respectively) and between UAI patients with and without SH (UAI SHC vs UAI SHK respectively) are reported in Table 2 . The prevalence of altered parameters of cortisol secretion was similar in BAI SHC vs UAI SHC and in BAI SHK vs UAI SHK patients. As BMI may influence BMD and we found that BMI was different among groups, the comparisons of Z-score values were adjusted for BMI by GLM.
In BAI SHC patients, age, BMI, gender, testosterone levels (in males), BMD, T2DM and DL were not statistically different as compared with BAI SHK, while the prevalence of AH was higher. The prevalence of FX tended to be higher in BAI SHC patients than in BAI SHK ones, even if without reaching the statistical significance (70 vs 46.4%, PZ0.07). A similar trend was found for the prevalence of T2DM and DL and for the years since menopause (in females). All female subjects in BAI SHC group were post-menopausal.
As compared with UAI SHK, in UAI SHC patients BMI and age were lower, and BMD (at both LS and FN) tended to be reduced (even without reaching the statistical significance, PZ0.07). The prevalence of FX was higher in UAI SHC than in UAI SHK group, while the years since menopause (in females), testosterone levels (in males), the prevalence of premenopausal females and of AH, T2DM and DL were similar between the two groups. The comparisons between SHC patients with BAI and UAI (BAI SHC vs UAI SHC respectively) and between SHK patients with BAI and UAI (BAI SHK vs UAI SHK respectively) are also reported in Table 2 . BAI SHC and UAI SHC patients showed similar age, BMI, gender, testosterone levels (in males), 1 mg DST and ACTH levels, while UFC levels were higher in the latter group. The BAI SHC group was not statistically different from UAI SHC as far as BMD, DL and T2DM were concerned. The prevalence of AH and FX and the years since menopause (in females) tended to be higher in BAI SHC than in UAI SHC, even without reaching the statistical significance (90 vs 58.5%, PZ0.07 and 70 vs 46.3%, PZ0.09 respectively).
BAI SHK showed similar age, years since menopause (in females), testosterone (in males), BMI, gender, cortisol secretion, LS BMD and the prevalence of premenopausal females, T2DM, DL and AH as compared with UAI SHK. On the contrary, FN BMD was lower and the prevalence of FX was higher in the former than in the latter group. Interestingly, BAI SHK patients showed a similar prevalence of FX to UAI SHC patients (Fig. 1) .
The parameters of bone metabolism were comparable among the four groups. The logistic regression analysis showed that the presence of FX was associated with the presence of BAI (odds ratio (OR) 2.6, 95% confidence interval (95% CI) 1.2-5.6, PZ0.016) after adjusting for the presence of SH (OR 1.77, 95% CI 0.85-3.7, PZ0.12), BMI (OR 1.06, 95% CI 0.98-1.13, PZ0.1), age (OR 1.07, 95% CI 1.04-1.11, PZ0.0001) and LS BMD (OR 1.31, 95% CI 1.03-1.67, PZ0.03). At variance, the presence of AH was independently associated with the presence of SH (OR 2.3, 95% CI 1.12-4.9, PZ0.02) but not with the presence of BAI (OR 1.08, 95% CI 0.5-2.4, PZ0.84), after adjusting for age (OR 1.07, 95% CI 1.04-1.1, P!0.0001) and BMI (OR 1.1, 95% CI 1.05-1.2, PZ0.001). These results were confirmed even after adding to the model the years since menopause or the presence/absence of menopause as independent variables (data not shown).
Discussion
In this study, we found that the patients with BAI had a lower BMD and a higher prevalence of FX than patients with UAI, after adjusting for cortisol secretion. On the contrary, the prevalence of AH was associated with the presence of SH, regardless of the presence of BAI. The other possible complications of SH (i.e. T2DM and DL) were similar between BAI and UAI patients.
The recorded prevalence of BAI (17.8%) is in accordance with that reported in the literature (2, 3) . Few data are available regarding the frequency of increased cortisol secretion in BAI patients as compared with UAI. A previous study showed a comparable prevalence of SH in BAI and UAI patients (7) , while a recent one described an increased SH frequency in BAI patients (11) . Our data showed a similar SH prevalence between the BAI and UAI subjects (23.4 vs 26.3% respectively, Table 1 ). A previous study showed an increased cortisol secretion in BAI than in UAI patients, possibly related to the different adenoma size (11) . At variance, in this study BAI and UAI patients showed a similar cortisol secretion, although BAI patients had a larger tumour mass.
The comparable frequency of SH in BAI and UAI patients is in accordance with the similar prevalence of T2DM, AH and DL between the two groups of patients. This is in keeping with previous studies reporting that BAI and UAI patients have a comparable prevalence of T2DM (11), AH and DL (7) . However, in this study, we found that, in spite of a similar cortisol secretion, BAI patients had a higher prevalence of FX (Table 1) . This is a novel finding as, to the best of our knowledge, no study evaluated bone involvement in patients with BAI as compared with those with UAI.
Looking at the role of SH in relation with the prevalence of T2DM, AH, DL and FX, we found that SH was associated with an increased prevalence of FX in UAI, as already reported (10, 13, 20, 21) , but not in BAI patients ( Table 2 ). The fact that FX appear to be associated with the presence of BAI, after adjusting for the presence of SH (as confirmed by the logistic regression analysis), suggests that bone involvement in BAI patients may be related to different causes in addition to the degree of the cortisol secretion. In keeping with this, the prevalence of FX was similar between BAI SHK and UAI SHC patients (Fig. 1) . Nevertheless, the prevalence of FX in BAI SHC tended to be higher than in BAI SHK, even if statistical significance was not reached, probably due to the small sample size. Therefore, it is likely that SH contributes to the bone damage also in BAI patients.
No previous studies compared the prevalence of AH, T2DM and DL in BAI and UAI patients in relation with SH. The presence of AH seemed to be higher in BAI SHC as compared with the other groups (Table 2) . However, after adjusting for age and BMI, AH was found to be independently associated with the presence of SH but not with the presence of BAI, as shown by the logistic regression analysis. Finally, we did not find a different prevalence of T2DM and DL among the four groups ( Table 2) . Several explanations of these findings may be postulated. First, a different disease duration and/or gonadal status might have played a role. Indeed, BAI may be the result of a misdiagnosed long-standing adrenal stimulation, by ACTH, that may lead to bilateral adrenocortical hyperplasia and to nodular transformation (4) . However, no data are available regarding the progressive transformation of Cushing's disease in BAI. However, bilateral masses may be the result of a genetic predisposition to adrenocortical cell proliferation (6) . If this was the case, the disease duration could be longer in BAI than in UAI patients. Nevertheless, this possible longer exposition to cortisol excess should have determined also a higher prevalence of metabolic complications that, on the contrary, was not found in our patients. Unfortunately, the lack of data regarding the disease duration does not consent to giving further insight in to this hypothesis.
Similarly, the different duration of menopause, which tended to be higher in BAI subjects as compared with the other groups, may have influenced the results. However, adding the years since menopause or the prevalence of premenopausal females in the logistic model did not modify the association between BAI and the presence of FX. In addition, the gonadal status was fully comparable between BAI SHK and UAI SHC patients, and, therefore, it cannot explain the similar prevalence of FX between these two groups.
Secondly, it is not possible to exclude a role of different aldosterone levels in BAI as compared with UAI. Unfortunately, we did not measure aldosterone levels in all patients but only in the hypertensive ones. It is possible, therefore, that some patients, though normotensive, were in fact affected with hyperaldosteronism. This may have influenced the prevalence of FX. Indeed, hyperaldosteronism has been recently associated with low BMD and FX in patients with adrenal incidentaloma (22) .
A third explanation may be related to the possible different pathogenesis of BAI and UAI (4, 5, 6) . Indeed, although entirely speculative, it could be hypothesised that BAI formation and bone damage may depend on the same cause. For example, the role of glucocorticoid receptor polymorphism on the pathogenesis of adrenal incidentaloma has been hypothesised. The N363S variant of the GR gene, associated with an increased sensitivity to glucocorticoids, seems to be more frequent in BAI than in UAI patients and controls, suggesting a possible role of this polymorphism in the formation of BAI (7) . However, the same polymorphism has been associated with an increased prevalence of FX in adrenal incidentalomas (23) . Therefore, it is not possible to exclude that a different frequency of the N363S variant of the GR gene may have led to both the formation of BAI and bone damage.
Finally, an explanation of the present findings may be related to the characteristic of SH per se. Indeed, in AI patients, cortisol secretion is a continuum from completely normal to clearly increased levels. Consequently, it is not possible to exclude that the available tools for diagnosing hypercortisolism may not be sensitive enough to detect the difference in cortisol secretion in these subjects (10) . Moreover, the criteria for diagnosing SH are still debated (9, 10) . However, in this study, this limit may be partially overcome by the fact that the prevalence of altered parameters of cortisol secretion is similar in BAI and UAI SHC and in BAI and UAI SHK patients. An important point is that in AI patients the cortisol secretion is highly variable, even in the same individual (10) . Therefore, our finding of a higher bone involvement in BAI patients as compared with UAI regardless of the presence of SH must be taken cautiously. Further studies are needed to confirm that the association between BAI and FX is really independent of cortisol secretion.
Unfortunately, due to budget restrictions, in this study bone turnover was evaluated only by measuring alkaline phosphatase total activity, which was found to be similar in BAI and UAI patients regardless of the presence of SH. Possibly, other more specific and sensitive indexes of bone turnover could have been more informative.
Notwithstanding these limits, the results of this study are of importance in clinical practice. Indeed, the finding that BAI patients have an increased prevalence of FX regardless of SH suggests that in these patients bone involvement should be assessed regardless of cortisol secretion. Moreover, as the presence of FX is related to the presence of BAI regardless of BMD, clinicians should be aware of the risk of FX and consider performing a spinal radiograph beside a BMD measurement in BAI patients. The finding that the prevalence of spine fractures was higher but the spine BMD was comparable between the groups might be considered surprising. However, in patients with SH, and in general in subjects with secondary forms of osteoporosis, bone quality is reduced (24) . Therefore, in these subjects bone density only partially explains the risk of fractures.
In conclusion, this study suggests that BMD is lower and the prevalence of FX is higher in BAI patients as compared with UAI after adjusting for the presence of SH. Further study should be performed to investigate the possible different origin of bone involvement in BAI as compared with UAI patients.
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